'''<big>Adverse effects by frequency:</big>'''<ref name = DM/><ref name = EMA/><ref name = EMC/><br>

 
'''Very common (>10% frequency):'''

 
{{colbegin|3}}

 
* Lower respiratory tract infection, including [[pneumonia]]

 
* Upper respiratory tract infection

 
* Rash

 
* [[Anemia]]

 
* [[Neutropenia]]

 
{{colend}}

 


 
'''Common (1-10% frequency):''''

 
{{colbegin|5}}

 
* [[Sepsis]]

 
* Herpes virus infection

 
* [[Urinary tract infection]]

 
* Febrile neutropenia

 
* [[Leucopenia]]

 
* [[Thrombocytopenia]]

 
* Anaphylactoid reactions

 
* Hypersensitivity

 
* Tachycardia

 
* Hypotension

 
* Hypertension

 
* Bronchospasm

 
* Hypoxia

 
* Dyspnoea (shortness of breath)

 
* Chest discomfort

 
* Pharyngolaryngeal pain

 
* Cough

 
* Nasal congestion

 
* Small bowel obstruction

 
* Diarrhoea

 
* Nausea

 
* Urticaria (hives)

 
* Itchiness

 
* Flushing

 
* Back pain

 
* [[Cytokine release syndrome]]

 
* Pyrexia (fever)

 
* Rigors

 
* Chills

 
* Hyperhidrosis

 
* Fatigue

 
{{colend}}

 


 
'''Uncommon (0.1-1% frequency):'''

 
{{colbegin|4}}

 
* [[Agranulocytosis]]

 
* Coagulopathy

 
* Red cell aplasia

 
* [[Lymphopenia]]

 
* Anaphylactic shock

 
* [[Tumour lysis syndrome]]

 
{{colend}}

 


 
'''Rare (<0.1% frequency):'''

 
* [[Hepatitis B]] infection or reactivation

 


 
Ofatumumab has received a [[black box warning]] regarding the potential for it to cause [[progressive multifocal leukoencephalopathy]] and [[hepatitis B]] reactivation.<ref name = MSR>{{cite web|title=Arzerra (ofatumumab) dosing, indications, interactions, and more|work=Medscape Reference|publisher=WebMD|accessdate=24 January 2014|url=http://reference.medscape.com/drug/arzerra-ofatumumab-999309#showall}}</ref> Likewise it is also advised that doctors watch cautiously for small bowel obstruction, neutropenia, thrombocytopenia, infusion reactions or an increased risk for infection.<ref name = MSR/>

 

